2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1647

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Abstract Number: 1648

Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Abstract Number: 1649

Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Abstract Number: 1650

Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Abstract Number: 1651

A Case Series on Patients on Tofacitinib in Combination with a Biologic
Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Abstract Number: 1653

Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Abstract Number: 1654

Differential Serum Protein Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features
Abstract Number: 1655

Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients
Abstract Number: 1656

Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Abstract Number: 1657

Soluble Biomarkers May Differentiate Psoriatic Arthritis from Osteoarthritis
Abstract Number: 1658

Regulatory Role of the IL-9/IL-9R System on Pannus Formation in Psoriatic Arthritis
Abstract Number: 1659

WITHDRAWN
Abstract Number: 1660

Role of Immune System Cells and Induction of Netosis-Mediated Cell Death in the Development of Atherosclerosis in Ankylosing Spondylitis
Abstract Number: 1661

Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].